1. Mission
2. The journal scope
3. Editorial Team
4. Readership and subscription
5. Types of Articles
6. Digital Data Archiving
7. Copyright Issue
8. Open Access Policy
9. Preprints and open-access
10. Article transfer service

  1. Mission

The rapid growth of the RNA field and fast broadening of its practical applications, particularly RNA therapeutics, underscores the significance of having a dedicated journal that propels the discipline forward by connecting foundational RNA research with practical uses of this biopolymer. The prediction that RNA will emerge as a key player in drug development has recently materialized into reality.  The establishment of an RNA nanomedicine-focused journal by the International Society for RNA Nanotechnology and Nanomedicine (myISRNN.org) aligns seamlessly with the society's overarching vision, mission, and goals. 

      2. The journal scope

This journal will encompass a comprehensive exploration of RNA and its chemical analogs, covering both its fundamental biochemical aspects and practical applications, with a particular emphasis on bridging the gap between these two domains. Fundamentally, the journal will explore the versatility of RNA structural composition and its related functional aspects. In terms of field application, it will spotlight RNA nanotechnology and RNA-based nanotherapeutics. The latter would encompass the applications of RNA both as drugs and as potential targets for other drugs. Special attention will be given to advancements in technology and the evolving landscape of RNA therapeutics, positioning it as the third milestone in pharmaceutical drug development.

Areas of interest include (but are not limited to) the following:

1. Multidisciplinary Approaches: biochemistry, biophysics, computation, and other disciplines and technologies with potential applications in studies of RNA and nanomedicine development.
2. RNA Therapeutics: exploration of therapeutic RNA nanoparticles, aptamers, siRNAs, miRNAs, riboswitches, ribozymes, and other small noncoding RNAs, emphasizing their capacity for in vivo delivery and roles in the treatment of conditions such as cancer and other diseases.
3. Small Molecules Targeting RNA: screening and design of chemical drugs aimed at binding and inhibiting biological function of targeted RNAs.
4. RNA Motility and Dynamics: investigation of RNA behavior both in vitro and in vivo, encompassing aspects including trafficking, biodistribution, and the conceptualization, design, and characterization of these dynamics.
5. RNA Interactions with Other Biological Molecules: exploration of the intricate interplay between RNA and other biological entities, including proteins, lipids, glucose, and the immune system.
6. RNA as Functional Materials: study of RNA's diverse roles as nanomaterials, functional polymers, antibody mimics, and biosensors.
7. Computational and Theoretical Studies: in-depth examination of interactions between different RNA molecules, coupled with computational studies and machine learning applications focused on understanding RNA structures and structure-activity relationships.
8. RNA Discovery and Regulation: discovery of novel RNA molecules and study of their in vivo processing and regulatory mechanisms.
9. RNA Structure Characterization: RNA structure visualization via X-ray crystallography, SAXS, NMR, AFM, cryo-EM, etc.

      3. Editorial Team

Editor in Chief: Peixuan Guo; The Ohio State University, Columbus, OH, USA

Executive Editor: Kirill Afonin; UNC Charolette, Charolette, NC, USA

Managing editor: Wayne Miles; The Ohio State University, Columbus, OH, USA

Meet the entire Editorial Team at: https://neoplasiaresearch.com/pms/index.php/JRNAN/about/editorialTeam

      4. Readership and subscription

The journal will be open access, with a reduced 50% cost for faculties within institutes and affiliations that subscribe to this journal. ISRNN members will receive 40% reduction in publication cost.  There will be no charge for the first three (3) years.

      5. Types of Articles

ORIGINAL RESEARCH ARTICLES: Full-length articles describe a significant finding with innovative ideas and approaches that focus on hypothesis-based research, and convincing data to support the finding and conclusion. The length should not exceed 6,000 words including body text and figure legends, a maximum of 8 figures within the article, no limit on supplemental data and figures (see below), no more than 70 references.  The abstract should be no more than 250 words with no more than one independent citation (author, journal, year, volume, and pages). The body should include an Introduction, Materials and Methods, Results, Discussions, and Conclusion. No content or figures in this category should have been published earlier.

LETTER OF COMMUNICATION: Dissemination of new findings with quick publication to the scientific community. The manuscript will not exceed 2,000 words, including the body text, figure legends, but not counting the references, and no more than 5 figures and 30 references, with abstract of less than 150 words.

REVIEWS: Critical reviews of selected important topics in RNA and Nanomedicine are solicited from established researchers. They should not exceed 5,000 words including body text and figure legends. Figure number should be less than 15, and references should be more than 220 except in the supplementary file(s). The abstract should be no more than 200 words. A conclusion section should be included at the end of the review consisting of not more than 150 words. Authors of Unsolicited Review manuscripts should first send the proposed title and outline for the specific topics with a description of the related background of the corresponding author for Editors' pre-submission approval. Previously published figures in this category should include permission for reuse from the publisher, and the consent of the author as a courtesy. 

PHILISOPHY, LOGIC, PERSPECTIVES IN RESEARCH AND SCIENCE: Invited articles or editorial comments that represent viewpoints, opinions in science and philosophy or logic in research design or approach, written for the general scientific readership in addition to the field of RNA and Nanomedicine. Length should not exceed 5,000 words including body text and figure legends. Authors wishing to submit an unsolicited article in these categories should send the topic, title, and outline of the planned content along with an introduction to the corresponding author and a brief 200-1,000-word synopsis to the editorial office as a pre-submission inquiry.

TECHNOLOGY, METHOD, AND COMMERCIALIZATION NOTES: Information about emerging or new technologies, crucial business development or FDA regulations on RNA nanotechnology commercialization issues, introduction to new RNA commercialization potential or products, interpretation of newly granted or PCT patents by the inventors, new RNA nanotechnology law, etc. Length of technical notes should not exceed 2,500 words including body text and figure legends, no more than 5 figures, and 15 references with an abstract of no more than 200 words.

      6. Digital Data Archiving

Neoplasia Research takes full responsibility for the online presence of each published article. To ensure the fulfilment of our commitment in cases of unforeseen events, the content of all journals has been deposited and archived in LOCKSS through the PKP Preservation Network. All articles published by Neoplasia Research Journals will be indexed in the indexing agencies wherein the respective journals are listed.

Neoplasia Research also allows its authors having a substantial self-archiving policy by which authors are free to self-archive their accepted manuscript in any institutional/disciplinary/state repository shortly after its first online publication by its journals. However, in these archives proper acknowledgment is required to be given to our journals as original source of publication. For this, a link may be provided with the archived article to the originally published article by Neoplasia Research.

      7. Copyright Issue

If the manuscript is accepted, the corresponding author will be asked to complete a form of 'Publishing Agreement' following the copyright policy or open access policy by Neoplasia Research.

For all works published by the Neoplasia Research, articles are considered as the intellectual property of the authors who reserve ownership of the copyright for their article, but allow all readers to download, reuse, reprint, modify, distribute, and/or copy articles in the journals by Neoplasia research provided the original authors and source are appropriately cited.

All Submissions to our journals must be original work, the copyright to which is not previously owned by anyone, elsewhere. Genuine and innovative work is always welcomed along with a strong encouragement for cross-disciplinary approaches.

Licensing Policy:

With the vision to increase the global exchange of knowledge, Neoplasia Research makes the research freely available to readers worldwide and provides immediate access to all of its published content by choosing the open-access publication policy.

All of our published articles are distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License, which permits the readers sharing, adaptation, distribution and reproduction and non-commercial use of our published articles in any medium or format, as long as appropriate credit to the original author(s) and the source is given by the user.

Authors of our published articles retain intellectual property rights of their articles (including research data); attribution rights for their published work; and may share their article provided it contains the end user license and the DOI link to its version in our journal’s archive.

Authors have copyright but grant license exclusive rights of their article to Neoplasia Research.

Authors of Neoplasia Research are given the right to use their articles, in full or in part, for scholarly but non-commercial purposes including:

• Distribution of soft/print copies of their articles to known researchers/colleagues for their personal use rather than the Commercial Use
• Inclusion of their article in a thesis or dissertation that will not be published commercially
• Distribution for classroom teaching (including electronic/print copies)
• Use in a subsequent compilation of their works
• Extending the Article to book-length form
• For the Preparation of any noncommercial derivative works

      8. Open Access Policy

To increase the exchange of knowledge globally Neoplasia Research adopts Open Access Policy which means it provides immediate open access to its content from any part of the world. The readers are required only to have an internet connection to approach our articles without paying any subscription fee. This policy also means that the authors grant the Neoplasia Research a comprehensive and unalterable right to distribute their published articles for any non-commercial purpose. All articles published in Neoplasia Research open access journals are distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/ . This implies that the published content will be permanently free for everyone around the world to read and download; permitting them to copy, redistribute, transmit and adapt the work, provided that the original source is appropriately cited.

      9. Preprints and open-access

Preprints can be shared anywhere at any time if the sharing or open-access policy of  Neoplasia Research is followed.

      10. Article transfer service

This journal uses the Neoplasia Research Transfer Service to find the most appropriate journal for your manuscript. If the editor feels that your manuscript is more appropriate for a sister journal, they might suggest your manuscript be transferred to another journal. If you agree, your manuscript will be reviewed by the new journal independently.